Skip to content
Triggering a Systemic Immune Response Against Cancer episode artwork

Oct 6, 2022 29 min

Triggering a Systemic Immune Response Against Cancer

from The Bio Report Hosted by Levine Media Group

Immune checkpoint inhibitors are transforming cancer care, but still have low response rates in most solid tumors. When cancer spreads to the liver, it can render immunotherapies ineffective because of the large number of immune-suppressive macrophages that are present there. Teclison has developed platform technology that chokes off tumors and activates the immune system against the cancer. The company said its technology can significantly enhances the therapeutic benefit of immunotherapies and can be leveraged to treat nearly all solid tumors. We spoke to Ray Lee, founder and chief medical officer of Teclison, about the company’s platform technology, it’s lead therapeutic candidate, and how it can trigger a systemic immune response.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Triggering a Systemic Immune Response Against Cancer

0:00 29:13

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of The Bio Report?

This episode is 29 minutes long.

When was this The Bio Report episode published?

This episode was published on October 6, 2022.

Can I download this The Bio Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.